Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,628 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,359 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06982222 | Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Aug 28, 2026 | clinicaltrials |
| NCT04364672 | Molecular Neuroimaging to Assess the Link Between Neuroinflammation and Cognitive Impairment in Breast Cancer | withdrawn | Phase 1 | 0 | University of Alabama at BirminghamOTHER | 0 | Jul 27, 2026 | clinicaltrials |
| NCT04348643 | Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT04273555 | Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging | withdrawn | Phase 1 / Phase 2 | 0 | University of Alabama at BirminghamOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT02856503 | Effect of High Dose Vitamin D on Cancer Biomarkers and Breast Cancer Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Eli Avisar, MDOTHER | 0 | Apr 17, 2026 | clinicaltrials |
| NCT06229392 | A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer | withdrawn | Phase 1 | 0 | Rush University Medical CenterOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07150767 | A Clinical Study to Explore the Safety, Tolerability, and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) Combined With Neoadjuvant Treatment for Locally Advanced Breast Cancer | withdrawn | Phase 1 | 0 | Beijing Bio-Targeting Therapeutics Technology Co., LtdINDUSTRY | 1 | Dec 2, 2025 | clinicaltrials |
| NCT05634954 | Study to Evaluate Safety and Dosimetry of [18F]GEH121224 in Patients With Locally Advanced or Metastatic Breast Cancer | withdrawn | Phase 1 | 0 | GE HealthcareINDUSTRY | 1 | Oct 23, 2025 | clinicaltrials |
| NCT05678205 | A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Artiva Biotherapeutics, Inc.INDUSTRY | 2 | Jul 30, 2025 | clinicaltrials |
| NCT06590558 | Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 3, 2025 | clinicaltrials |
| NCT01349088 | Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT04418219 | Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Thomas Jefferson UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT06938711 | A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Context Therapeutics Inc.INDUSTRY | 1 | Apr 22, 2025 | clinicaltrials |
| NCT05940844 | Study of OB-002 in Patients With Refractory Metastatic Cancer | withdrawn | Phase 1 | 0 | Orion Biotechnology Polska Sp. z o.o.INDUSTRY | 0 | Apr 9, 2025 | clinicaltrials |
| NCT03175666 | QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy | withdrawn | Phase 1 / Phase 2 | 0 | ImmunityBio, Inc.INDUSTRY | 0 | Feb 21, 2025 | clinicaltrials |
| NCT06341647 | Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201 | withdrawn | Phase 1 | 0 | GC Cell CorporationINDUSTRY | 0 | Jan 24, 2025 | clinicaltrials |
| NCT05655598 | TAS-116 Plus Palbociclib in Breast and Rb-null Cancer | withdrawn | Phase 1 | 0 | Brown UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05039931 | A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid Tumors | withdrawn | Phase 1 | 0 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 18, 2024 | clinicaltrials |
| NCT06137651 | Trotabresib in Combination With Vinorelbine and Radiation Therapy for the Treatment of HER2+ Breast Cancer With Central Nervous System or Leptomeningeal Metastasis | withdrawn | Phase 1 | 0 | Northwestern UniversityOTHER | 1 | Apr 1, 2024 | clinicaltrials |
| NCT04756505 | Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Dec 27, 2023 | clinicaltrials |
| NCT04602117 | ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer | withdrawn | Phase 1 | 0 | QuantumLeap Healthcare CollaborativeOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT04054752 | Vaccine Response With NT-I7 | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | Nov 2, 2023 | clinicaltrials |
| NCT03803761 | A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Sep 25, 2023 | clinicaltrials |
| NCT00455039 | INST 0514C- Biologic Correlative Study: Trial of GW572016 in HER2 Overexpressing Breast Cancer Patients | withdrawn | Phase 1 / Phase 2 | 0 | University of New MexicoOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT05191004 | Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC | withdrawn | Phase 1 / Phase 2 | 0 | Nuvation Bio Inc.INDUSTRY | 1 | Jul 11, 2023 | clinicaltrials |
| NCT04896320 | Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Cancer.(2019-101826) | withdrawn | Phase 1 / Phase 2 | 0 | Providence Health & ServicesOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05431582 | Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jun 15, 2023 | clinicaltrials |
| NCT05774886 | Implantable Microdevice for TNBC - Pilot Study | withdrawn | Phase 1 | 0 | Dana-Farber Cancer InstituteOTHER | 0 | May 18, 2023 | clinicaltrials |
| NCT04872608 | A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer | withdrawn | Phase 1 | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 28, 2023 | clinicaltrials |
| NCT03121989 | Study to Evaluate the Feasibility of 13-C Pyruvate Imaging in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy(LABC) | withdrawn | Phase 1 | 0 | Sunnybrook Health Sciences CentreOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT04252768 | A Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients to Test a New Schedule of Efti (IMP321, Eftilagimod Alpha) as Adjunctive to a Weekly Treatment Regimen of Paclitaxel(AIPAC-002) | withdrawn | Phase 1 | 0 | Immutep S.A.S.INDUSTRY | 0 | Mar 22, 2023 | clinicaltrials |
| NCT04826016 | POL6326 (Balixafortide) Plus Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast Cancer(POLTER) | withdrawn | Phase 1 / Phase 2 | 0 | MedSIROTHER | 0 | Mar 20, 2023 | clinicaltrials |
| NCT04316169 | Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer | withdrawn | Phase 1 | 0 | Medical College of WisconsinOTHER | 1 | Dec 23, 2022 | clinicaltrials |
| NCT05093387 | SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer | withdrawn | Phase 1 | 0 | Northwestern UniversityOTHER | 1 | Nov 15, 2022 | clinicaltrials |
| NCT02569489 | Dose Escalation Study of HBI-8000 in Combination With Paclitaxel and Trastuzumab in Women With Advanced or Metastatic HER2+ Breast Cancer | withdrawn | Phase 1 | 0 | HUYABIO International, LLC.INDUSTRY | 0 | Jul 18, 2022 | clinicaltrials |
| NCT02562612 | Study of SM-88 in Advanced Cancers | withdrawn | Phase 1 / Phase 2 | 0 | Tyme, IncINDUSTRY | 0 | Jul 1, 2022 | clinicaltrials |
| NCT04512261 | TOPAZ: Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Patients With HER2-Positive Breast Cancer Brain Metastases(TOPAZ) | withdrawn | Phase 1 / Phase 2 | 0 | Reva BashoOTHER | 1 | Jul 1, 2022 | clinicaltrials |
| NCT02035085 | 19F Hot Spot MRI of Human Adipose-derived Stem Cells for Breast Reconstruction(CS-1000) | withdrawn | Phase 1 | 0 | Johns Hopkins UniversityOTHER | 1 | Jun 27, 2022 | clinicaltrials |
| NCT04762901 | LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer | withdrawn | Phase 1 | 0 | Wake Forest University Health SciencesOTHER | 0 | Apr 26, 2022 | clinicaltrials |
| NCT05234606 | A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Silverback TherapeuticsINDUSTRY | 0 | Apr 12, 2022 | clinicaltrials |
| NCT03682744 | CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC) | withdrawn | Phase 1 | 0 | Sorrento Therapeutics, Inc.INDUSTRY | 1 | Apr 6, 2022 | clinicaltrials |
| NCT02427581 | Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy | withdrawn | Phase 1 | 0 | Washington University School of MedicineOTHER | 0 | Mar 10, 2022 | clinicaltrials |
| NCT03634150 | Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Immune System Key LtdINDUSTRY | 1 | Oct 26, 2021 | clinicaltrials |
| NCT04585724 | Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases | withdrawn | Phase 1 | 0 | Emory UniversityOTHER | 0 | Oct 18, 2021 | clinicaltrials |
| NCT04655183 | Study of M4344 in Combination With Niraparib | withdrawn | Phase 1 / Phase 2 | 0 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 0 | Jun 30, 2021 | clinicaltrials |
| NCT04498520 | Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer | withdrawn | Phase 1 | 0 | Pamela MunsterOTHER | 0 | May 18, 2021 | clinicaltrials |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | withdrawn | Phase 1 / Phase 2 | 0 | NKGen Biotech, Inc.INDUSTRY | 0 | May 12, 2021 | clinicaltrials |
| NCT02038699 | A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Jazz PharmaceuticalsINDUSTRY | 1 | Apr 30, 2021 | clinicaltrials |
| NCT02336984 | A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS | withdrawn | Phase 1 / Phase 2 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 11, 2021 | clinicaltrials |
Data updated 22 days agoSource updated Aug 28, 2026source: clinicaltrials